Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.50 - $16.63
Previous CloseN/A
Volume62.24K
Average Volume (3M)263.21K
Market Cap
$386.14M
Enterprise Value$412.58M
Total Cash (Recent Filing)€251.94M
Total Debt (Recent Filing)€55.46M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Jun 02, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding63,418,750
10 Day Avg. Volume162,938
30 Day Avg. Volume263,209
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)83.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.50Price Target Upside437.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsObefazimod's clinical profile, including high rates of clinical remission and a generally clean safety profile in a convenient oral form, remains compelling.
Financial StabilityAbivax ended 2024 with €144.2M in cash, which is expected to fund operations into Q4 2025.
Market PotentialObefazimod is well-positioned to address the unmet need for safe therapies in refractory ulcerative colitis patients, due to its novel mechanism of action and clean safety profile.
Bears Say
Financial PerformanceThe net loss per share in 2024 was €176.2M, or (€2.80/share).
Research And Development CostsR&D expenses totaled €146.5M in 2024, and SG&A and marketing costs totaled €38.9M.
Stock MovementThere is a possibility that shares could remain range-bound until investors are presented with more definitive data.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.80% Mutual Funds
38.33% Other Institutional Investors
60.88% Public Companies and
Individual Investors
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.50 and its highest was $16.63 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $386.14M.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Jun 02, 2025 which is in 59 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Mar 24, 2025. The company reported -$0.793 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$0.066.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.76.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 63,418,750 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.793 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -0.136%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
---
Abivax SA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (437.19% Upside)
$32.50 (437.19% Upside)
Hedge Fund Trend
Decreased
By 619.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.90%
12-Months-Change
Fundamentals
Return on Equity
-147.48%
Trailing 12-Months
Asset Growth
-41.18%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
---
ABVX Stock 12 Month Forecast
Average Price Target
$32.50
▲(437.19% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Neurocrine
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering ABVX
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-34.55%
reiterated a buy rating 11 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.55% per trade.
---